Please note that this product was withdrawn from the Union Register of orphan medicinal products in January 2020 on request of the sponsor.
On 10 July 2008, orphan designation (EU/3/08/554) was granted by the European Commission to Lung Rx Limited, United Kingdom, for beraprost sodium (modified release tablet) for the treatment of pulmonary arterial hypertension.
The sponsorship was transferred to IDEA Innovative Drugs European Associates Limited, United Kingdom, in February 2012.
In December 2012, Innovative Drug European Associates Limited changed name to IDEA Innovative Drug European Associates Limited.
The sponsorship was transferred to IDEA Innovative Drug European Associates (Ireland) Limited, Republic of Ireland, in February 2019.
|Disease / condition||
Treatment of pulmonary arterial hypertension
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.